JP2005502332A

JP2005502332A - Ｇｍｇ−２ポリヌクレオチド及びポリペプチド並びにそれらの使用

Ｇｍｇ−２ポリヌクレオチド及びポリペプチド並びにそれらの使用 Download PDF

Info

Publication number: JP2005502332A
Authority: JP; Japan
Prior art keywords: polypeptide; ggmg; gmg; polypeptide fragment; sequence
Prior art date: 2001-07-26
Legal status : Pending

Application number

JP2003515664A

Other languages

English (en)

Japanese (ja)

Other versions

JP2005502332A5 (enExample

Inventor

タナカ，ヒロアキ

ルーカス，ジョン

スカリア，アーロン

ディアリナス，デノ

Original Assignee

ジェンセットソシエテアノニム

Priority date

2001-07-26

Filing date

2002-07-25

Publication date

2005-01-27

2002-07-25 Application filed by ジェンセットソシエテアノニム filed Critical ジェンセットソシエテアノニム

2005-01-27 Publication of JP2005502332A publication Critical patent/JP2005502332A/ja

2005-11-17 Publication of JP2005502332A5 publication Critical patent/JP2005502332A5/ja

Status Pending legal-status Critical Current

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 532
102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 525
229920001184 polypeptide Polymers 0.000 title claims abstract description 520
239000002157 polynucleotide Substances 0.000 title claims description 178
108091033319 polynucleotide Proteins 0.000 title claims description 177
102000040430 polynucleotide Human genes 0.000 title claims description 177
239000012634 fragment Substances 0.000 claims abstract description 406
235000001014 amino acid Nutrition 0.000 claims description 193
150000001413 amino acids Chemical class 0.000 claims description 177
238000000034 method Methods 0.000 claims description 160
239000000203 mixture Substances 0.000 claims description 79
239000013598 vector Substances 0.000 claims description 74
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 54
235000018417 cysteine Nutrition 0.000 claims description 45
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 42
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 41
235000021588 free fatty acids Nutrition 0.000 claims description 33
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 15
230000000295 complement effect Effects 0.000 claims description 10
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 claims 4
208000008589 Obesity Diseases 0.000 abstract description 77
235000020824 obesity Nutrition 0.000 abstract description 76
230000004580 weight loss Effects 0.000 abstract description 60
150000001875 compounds Chemical class 0.000 abstract description 28
206010020772 Hypertension Diseases 0.000 abstract description 18
201000001320 Atherosclerosis Diseases 0.000 abstract description 17
206010012601 diabetes mellitus Diseases 0.000 abstract description 13
208000037765 diseases and disorders Diseases 0.000 abstract description 13
208000031226 Hyperlipidaemia Diseases 0.000 abstract description 9
238000011160 research Methods 0.000 abstract description 3
230000005180 public health Effects 0.000 abstract description 2
229940024606 amino acid Drugs 0.000 description 177
210000004027 cell Anatomy 0.000 description 173
230000000694 effects Effects 0.000 description 142
108090000623 proteins and genes Proteins 0.000 description 105
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 92
125000003729 nucleotide group Chemical group 0.000 description 85
208000001072 type 2 diabetes mellitus Diseases 0.000 description 85
239000002773 nucleotide Substances 0.000 description 83
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 65
102000004169 proteins and genes Human genes 0.000 description 65
241000282414 Homo sapiens Species 0.000 description 61
235000018102 proteins Nutrition 0.000 description 60
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 58
229960001031 glucose Drugs 0.000 description 58
238000011282 treatment Methods 0.000 description 58
208000016261 weight loss Diseases 0.000 description 58
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 57
239000008103 glucose Substances 0.000 description 57
230000014509 gene expression Effects 0.000 description 53
125000003275 alpha amino acid group Chemical group 0.000 description 51
102000004877 Insulin Human genes 0.000 description 46
108090001061 Insulin Proteins 0.000 description 46
229940125396 insulin Drugs 0.000 description 46
206010022489 Insulin Resistance Diseases 0.000 description 43
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 39
238000000338 in vitro Methods 0.000 description 38
150000007523 nucleic acids Chemical class 0.000 description 37
241000124008 Mammalia Species 0.000 description 36
150000002632 lipids Chemical class 0.000 description 35
238000001727 in vivo Methods 0.000 description 34
235000005911 diet Nutrition 0.000 description 33
208000035475 disorder Diseases 0.000 description 33
210000002381 plasma Anatomy 0.000 description 33
201000010099 disease Diseases 0.000 description 32
230000001965 increasing effect Effects 0.000 description 30
102000039446 nucleic acids Human genes 0.000 description 30
108020004707 nucleic acids Proteins 0.000 description 30
238000006467 substitution reaction Methods 0.000 description 30
241001465754 Metazoa Species 0.000 description 29
RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 29
208000002705 Glucose Intolerance Diseases 0.000 description 26
201000009104 prediabetes syndrome Diseases 0.000 description 25
108020004414 DNA Proteins 0.000 description 23
241000282412 Homo Species 0.000 description 22
235000013350 formula milk Nutrition 0.000 description 22
238000003776 cleavage reaction Methods 0.000 description 21
230000007017 scission Effects 0.000 description 21
235000019197 fats Nutrition 0.000 description 20
210000001519 tissue Anatomy 0.000 description 20
241000699666 Mus <mouse, genus> Species 0.000 description 19
210000004369 blood Anatomy 0.000 description 19
239000008280 blood Substances 0.000 description 19
210000003205 muscle Anatomy 0.000 description 19
238000002360 preparation method Methods 0.000 description 19
230000037396 body weight Effects 0.000 description 18
230000002265 prevention Effects 0.000 description 18
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 18
239000002299 complementary DNA Substances 0.000 description 17
238000012217 deletion Methods 0.000 description 17
230000037430 deletion Effects 0.000 description 17
230000000378 dietary effect Effects 0.000 description 17
230000012010 growth Effects 0.000 description 17
238000000746 purification Methods 0.000 description 17
230000004584 weight gain Effects 0.000 description 17
235000019786 weight gain Nutrition 0.000 description 17
230000037213 diet Effects 0.000 description 16
-1 especially in muscle Substances 0.000 description 16
235000013336 milk Nutrition 0.000 description 16
239000008267 milk Substances 0.000 description 16
210000004080 milk Anatomy 0.000 description 16
230000003647 oxidation Effects 0.000 description 16
238000007254 oxidation reaction Methods 0.000 description 16
230000001105 regulatory effect Effects 0.000 description 16
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 15
125000000539 amino acid group Chemical group 0.000 description 15
239000005557 antagonist Substances 0.000 description 15
239000013604 expression vector Substances 0.000 description 15
239000000523 sample Substances 0.000 description 15
239000000126 substance Substances 0.000 description 15
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 14
108091026890 Coding region Proteins 0.000 description 14
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 14
208000019622 heart disease Diseases 0.000 description 14
230000003902 lesion Effects 0.000 description 14
229920001223 polyethylene glycol Polymers 0.000 description 14
229940122355 Insulin sensitizer Drugs 0.000 description 13
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 13
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 13
239000002537 cosmetic Substances 0.000 description 13
230000002608 insulinlike Effects 0.000 description 13
NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 13
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 12
102000016267 Leptin Human genes 0.000 description 12
108010092277 Leptin Proteins 0.000 description 12
206010028980 Neoplasm Diseases 0.000 description 12
239000002202 Polyethylene glycol Substances 0.000 description 12
210000004899 c-terminal region Anatomy 0.000 description 12
239000003814 drug Substances 0.000 description 12
108020001507 fusion proteins Proteins 0.000 description 12
102000037865 fusion proteins Human genes 0.000 description 12
229940039781 leptin Drugs 0.000 description 12
210000004185 liver Anatomy 0.000 description 12
238000004519 manufacturing process Methods 0.000 description 12
208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 12
108091028043 Nucleic acid sequence Proteins 0.000 description 11
108700019146 Transgenes Proteins 0.000 description 11
241000700605 Viruses Species 0.000 description 11
210000000577 adipose tissue Anatomy 0.000 description 11
210000003734 kidney Anatomy 0.000 description 11
230000037356 lipid metabolism Effects 0.000 description 11
238000012423 maintenance Methods 0.000 description 11
230000002503 metabolic effect Effects 0.000 description 11
229930182817 methionine Natural products 0.000 description 11
230000000291 postprandial effect Effects 0.000 description 11
230000002829 reductive effect Effects 0.000 description 11
230000009261 transgenic effect Effects 0.000 description 11
108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 description 10
102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 description 10
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 10
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 10
238000007792 addition Methods 0.000 description 10
201000011510 cancer Diseases 0.000 description 10
230000007423 decrease Effects 0.000 description 10
210000002966 serum Anatomy 0.000 description 10
208000011580 syndromic disease Diseases 0.000 description 10
238000012360 testing method Methods 0.000 description 10
206010019280 Heart failures Diseases 0.000 description 9
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 9
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 9
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 9
241000699670 Mus sp. Species 0.000 description 9
241001494479 Pecora Species 0.000 description 9
238000004458 analytical method Methods 0.000 description 9
239000003795 chemical substances by application Substances 0.000 description 9
208000029078 coronary artery disease Diseases 0.000 description 9
210000005075 mammary gland Anatomy 0.000 description 9
108020004999 messenger RNA Proteins 0.000 description 9
230000002093 peripheral effect Effects 0.000 description 9
201000010065 polycystic ovary syndrome Diseases 0.000 description 9
108091032973 (ribonucleotides)n+m Proteins 0.000 description 8
241000283690 Bos taurus Species 0.000 description 8
208000032841 Bulimia Diseases 0.000 description 8
206010006550 Bulimia nervosa Diseases 0.000 description 8
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 8
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 8
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 8
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 8
239000004472 Lysine Substances 0.000 description 8
241000283973 Oryctolagus cuniculus Species 0.000 description 8
208000006011 Stroke Diseases 0.000 description 8
229930006000 Sucrose Natural products 0.000 description 8
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 8
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 8
229940079593 drug Drugs 0.000 description 8
230000004927 fusion Effects 0.000 description 8
230000002068 genetic effect Effects 0.000 description 8
239000003550 marker Substances 0.000 description 8
230000004048 modification Effects 0.000 description 8
238000012986 modification Methods 0.000 description 8
230000035772 mutation Effects 0.000 description 8
239000000047 product Substances 0.000 description 8
230000000580 secretagogue effect Effects 0.000 description 8
239000005720 sucrose Substances 0.000 description 8
208000030507 AIDS Diseases 0.000 description 7
241000283707 Capra Species 0.000 description 7
208000002249 Diabetes Complications Diseases 0.000 description 7
239000004471 Glycine Substances 0.000 description 7
201000001431 Hyperuricemia Diseases 0.000 description 7
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 7
239000004365 Protease Substances 0.000 description 7
208000017442 Retinal disease Diseases 0.000 description 7
206010038923 Retinopathy Diseases 0.000 description 7
230000002159 abnormal effect Effects 0.000 description 7
208000022531 anorexia Diseases 0.000 description 7
230000027455 binding Effects 0.000 description 7
150000001720 carbohydrates Chemical class 0.000 description 7
230000008859 change Effects 0.000 description 7
210000004351 coronary vessel Anatomy 0.000 description 7
206010061428 decreased appetite Diseases 0.000 description 7
230000004190 glucose uptake Effects 0.000 description 7
210000001624 hip Anatomy 0.000 description 7
238000002744 homologous recombination Methods 0.000 description 7
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 7
229960000310 isoleucine Drugs 0.000 description 7
239000002502 liposome Substances 0.000 description 7
210000001161 mammalian embryo Anatomy 0.000 description 7
239000011159 matrix material Substances 0.000 description 7
238000005259 measurement Methods 0.000 description 7
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 7
201000001119 neuropathy Diseases 0.000 description 7
230000007823 neuropathy Effects 0.000 description 7
208000013441 ocular lesion Diseases 0.000 description 7
229940125395 oral insulin Drugs 0.000 description 7
208000033808 peripheral neuropathy Diseases 0.000 description 7
230000004044 response Effects 0.000 description 7
241000894007 species Species 0.000 description 7
230000014616 translation Effects 0.000 description 7
150000003626 triacylglycerols Chemical class 0.000 description 7
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 7
239000004475 Arginine Substances 0.000 description 6
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 6
206010006895 Cachexia Diseases 0.000 description 6
241000282472 Canis lupus familiaris Species 0.000 description 6
108020004705 Codon Proteins 0.000 description 6
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 6
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 6
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 6
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 6
102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 6
108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 6
108700026244 Open Reading Frames Proteins 0.000 description 6
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 6
108010076504 Protein Sorting Signals Proteins 0.000 description 6
241000700159 Rattus Species 0.000 description 6
210000001789 adipocyte Anatomy 0.000 description 6
235000004279 alanine Nutrition 0.000 description 6
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 6
235000009582 asparagine Nutrition 0.000 description 6
229960001230 asparagine Drugs 0.000 description 6
235000003704 aspartic acid Nutrition 0.000 description 6
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 6
230000004071 biological effect Effects 0.000 description 6
230000008512 biological response Effects 0.000 description 6
239000013611 chromosomal DNA Substances 0.000 description 6
230000001276 controlling effect Effects 0.000 description 6
230000003247 decreasing effect Effects 0.000 description 6
238000011161 development Methods 0.000 description 6
230000018109 developmental process Effects 0.000 description 6
239000003623 enhancer Substances 0.000 description 6
235000013922 glutamic acid Nutrition 0.000 description 6
239000004220 glutamic acid Substances 0.000 description 6
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 6
235000009200 high fat diet Nutrition 0.000 description 6
230000006801 homologous recombination Effects 0.000 description 6
235000020256 human milk Nutrition 0.000 description 6
210000004251 human milk Anatomy 0.000 description 6
208000015181 infectious disease Diseases 0.000 description 6
206010025135 lupus erythematosus Diseases 0.000 description 6
235000015097 nutrients Nutrition 0.000 description 6
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 6
235000008729 phenylalanine Nutrition 0.000 description 6
230000008488 polyadenylation Effects 0.000 description 6
238000012545 processing Methods 0.000 description 6
238000001890 transfection Methods 0.000 description 6
238000013519 translation Methods 0.000 description 6
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 6
206010048828 underweight Diseases 0.000 description 6
241000701447 unidentified baculovirus Species 0.000 description 6
241001430294 unidentified retrovirus Species 0.000 description 6
239000004474 valine Substances 0.000 description 6
125000001433 C-terminal amino-acid group Chemical group 0.000 description 5
241000588724 Escherichia coli Species 0.000 description 5
206010061218 Inflammation Diseases 0.000 description 5
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 5
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 5
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 5
102000035195 Peptidases Human genes 0.000 description 5
108091005804 Peptidases Proteins 0.000 description 5
241000282898 Sus scrofa Species 0.000 description 5
208000037063 Thinness Diseases 0.000 description 5
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 5
239000004473 Threonine Substances 0.000 description 5
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 5
230000015572 biosynthetic process Effects 0.000 description 5
235000014633 carbohydrates Nutrition 0.000 description 5
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 5
230000006378 damage Effects 0.000 description 5
238000005265 energy consumption Methods 0.000 description 5
210000003527 eukaryotic cell Anatomy 0.000 description 5
235000013305 food Nutrition 0.000 description 5
230000006870 function Effects 0.000 description 5
230000002538 fungal effect Effects 0.000 description 5
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 5
230000004054 inflammatory process Effects 0.000 description 5
125000005647 linker group Chemical group 0.000 description 5
239000000463 material Substances 0.000 description 5
230000001404 mediated effect Effects 0.000 description 5
235000019419 proteases Nutrition 0.000 description 5
230000009467 reduction Effects 0.000 description 5
238000006722 reduction reaction Methods 0.000 description 5
230000010076 replication Effects 0.000 description 5
210000003296 saliva Anatomy 0.000 description 5
150000003839 salts Chemical class 0.000 description 5
239000000243 solution Substances 0.000 description 5
208000024891 symptom Diseases 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
238000013518 transcription Methods 0.000 description 5
230000035897 transcription Effects 0.000 description 5
238000012546 transfer Methods 0.000 description 5
230000001052 transient effect Effects 0.000 description 5
210000002700 urine Anatomy 0.000 description 5
208000019553 vascular disease Diseases 0.000 description 5
230000003612 virological effect Effects 0.000 description 5
FFEKJBVVAJTQST-WLHGVMLRSA-N (e)-but-2-enedioic acid;1,1-dimethyl-2-(2-morpholin-4-ylphenyl)guanidine Chemical compound OC(=O)\C=C\C(O)=O.CN(C)C(N)=NC1=CC=CC=C1N1CCOCC1 FFEKJBVVAJTQST-WLHGVMLRSA-N 0.000 description 4
229920002307 Dextran Polymers 0.000 description 4
241000196324 Embryophyta Species 0.000 description 4
241000238631 Hexapoda Species 0.000 description 4
206010060378 Hyperinsulinaemia Diseases 0.000 description 4
206010056997 Impaired fasting glucose Diseases 0.000 description 4
108090001030 Lipoproteins Proteins 0.000 description 4
102000004895 Lipoproteins Human genes 0.000 description 4
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 4
108020005067 RNA Splice Sites Proteins 0.000 description 4
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
241000282887 Suidae Species 0.000 description 4
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
241000251539 Vertebrata <Metazoa> Species 0.000 description 4
239000000556 agonist Substances 0.000 description 4
230000008901 benefit Effects 0.000 description 4
125000003636 chemical group Chemical group 0.000 description 4
238000006243 chemical reaction Methods 0.000 description 4
238000004587 chromatography analysis Methods 0.000 description 4
210000000349 chromosome Anatomy 0.000 description 4
238000001212 derivatisation Methods 0.000 description 4
238000003745 diagnosis Methods 0.000 description 4
210000002257 embryonic structure Anatomy 0.000 description 4
210000002919 epithelial cell Anatomy 0.000 description 4
238000003205 genotyping method Methods 0.000 description 4
210000003494 hepatocyte Anatomy 0.000 description 4
238000004128 high performance liquid chromatography Methods 0.000 description 4
210000005260 human cell Anatomy 0.000 description 4
230000003451 hyperinsulinaemic effect Effects 0.000 description 4
201000008980 hyperinsulinism Diseases 0.000 description 4
230000001939 inductive effect Effects 0.000 description 4
230000028709 inflammatory response Effects 0.000 description 4
230000003993 interaction Effects 0.000 description 4
230000004060 metabolic process Effects 0.000 description 4
239000002245 particle Substances 0.000 description 4
HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 4
229920000642 polymer Polymers 0.000 description 4
102000054765 polymorphisms of proteins Human genes 0.000 description 4
230000002028 premature Effects 0.000 description 4
239000013615 primer Substances 0.000 description 4
230000006337 proteolytic cleavage Effects 0.000 description 4
102000005962 receptors Human genes 0.000 description 4
108020003175 receptors Proteins 0.000 description 4
238000010188 recombinant method Methods 0.000 description 4
230000001177 retroviral effect Effects 0.000 description 4
230000028327 secretion Effects 0.000 description 4
238000010561 standard procedure Methods 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
241000701161 unidentified adenovirus Species 0.000 description 4
FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 3
102000029816 Collagenase Human genes 0.000 description 3
108060005980 Collagenase Proteins 0.000 description 3
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
241000282326 Felis catus Species 0.000 description 3
241000233866 Fungi Species 0.000 description 3
208000031773 Insulin resistance syndrome Diseases 0.000 description 3
229940122199 Insulin secretagogue Drugs 0.000 description 3
206010033307 Overweight Diseases 0.000 description 3
241000288906 Primates Species 0.000 description 3
241000283984 Rodentia Species 0.000 description 3
240000004808 Saccharomyces cerevisiae Species 0.000 description 3
WBAXJMCUFIXCNI-WDSKDSINSA-N Ser-Pro Chemical group OC[C@H](N)C(=O)N1CCC[C@H]1C(O)=O WBAXJMCUFIXCNI-WDSKDSINSA-N 0.000 description 3
108091081024 Start codon Proteins 0.000 description 3
208000024248 Vascular System injury Diseases 0.000 description 3
208000012339 Vascular injury Diseases 0.000 description 3
239000002253 acid Substances 0.000 description 3
238000001042 affinity chromatography Methods 0.000 description 3
QWCKQJZIFLGMSD-UHFFFAOYSA-N alpha-aminobutyric acid Chemical compound CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 3
230000000890 antigenic effect Effects 0.000 description 3
238000013459 approach Methods 0.000 description 3
210000004436 artificial bacterial chromosome Anatomy 0.000 description 3
238000003556 assay Methods 0.000 description 3
210000002459 blastocyst Anatomy 0.000 description 3
210000004556 brain Anatomy 0.000 description 3
229940077731 carbohydrate nutrients Drugs 0.000 description 3
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
229960002424 collagenase Drugs 0.000 description 3
238000004590 computer program Methods 0.000 description 3
238000007796 conventional method Methods 0.000 description 3
238000012937 correction Methods 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
208000009190 disseminated intravascular coagulation Diseases 0.000 description 3
238000001962 electrophoresis Methods 0.000 description 3
238000005516 engineering process Methods 0.000 description 3
230000002708 enhancing effect Effects 0.000 description 3
238000000605 extraction Methods 0.000 description 3
238000010353 genetic engineering Methods 0.000 description 3
239000000710 homodimer Substances 0.000 description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
201000010066 hyperandrogenism Diseases 0.000 description 3
230000000977 initiatory effect Effects 0.000 description 3
238000003780 insertion Methods 0.000 description 3
230000037431 insertion Effects 0.000 description 3
230000010354 integration Effects 0.000 description 3
238000005304 joining Methods 0.000 description 3
150000002576 ketones Chemical class 0.000 description 3
208000032839 leukemia Diseases 0.000 description 3
239000003446 ligand Substances 0.000 description 3
210000004962 mammalian cell Anatomy 0.000 description 3
235000012054 meals Nutrition 0.000 description 3
238000000691 measurement method Methods 0.000 description 3
238000000520 microinjection Methods 0.000 description 3
210000000663 muscle cell Anatomy 0.000 description 3
210000000287 oocyte Anatomy 0.000 description 3
239000013612 plasmid Substances 0.000 description 3
229940012957 plasmin Drugs 0.000 description 3
125000006239 protecting group Chemical group 0.000 description 3
238000001742 protein purification Methods 0.000 description 3
238000012216 screening Methods 0.000 description 3
230000003248 secreting effect Effects 0.000 description 3
238000000926 separation method Methods 0.000 description 3
210000001082 somatic cell Anatomy 0.000 description 3
238000003860 storage Methods 0.000 description 3
230000002459 sustained effect Effects 0.000 description 3
230000009466 transformation Effects 0.000 description 3
230000032258 transport Effects 0.000 description 3
239000013638 trimer Substances 0.000 description 3
GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 3
229960001641 troglitazone Drugs 0.000 description 3
GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 3
239000013603 viral vector Substances 0.000 description 3
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
229920000936 Agarose Polymers 0.000 description 2
WPWUFUBLGADILS-WDSKDSINSA-N Ala-Pro Chemical group C[C@H](N)C(=O)N1CCC[C@H]1C(O)=O WPWUFUBLGADILS-WDSKDSINSA-N 0.000 description 2
206010002383 Angina Pectoris Diseases 0.000 description 2
206010059245 Angiopathy Diseases 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
RKWGIWYCVPQPMF-UHFFFAOYSA-N Chloropropamide Chemical compound CCCNC(=O)NS(=O)(=O)C1=CC=C(Cl)C=C1 RKWGIWYCVPQPMF-UHFFFAOYSA-N 0.000 description 2
102000008186 Collagen Human genes 0.000 description 2
108010035532 Collagen Proteins 0.000 description 2
241000699802 Cricetulus griseus Species 0.000 description 2
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 2
206010051055 Deep vein thrombosis Diseases 0.000 description 2
241000702421 Dependoparvovirus Species 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
108700039691 Genetic Promoter Regions Proteins 0.000 description 2
108010093488 His-His-His-His-His-His Proteins 0.000 description 2
101000697936 Homo sapiens Attractin Proteins 0.000 description 2
101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 2
241001135569 Human adenovirus 5 Species 0.000 description 2
241000282620 Hylobates sp. Species 0.000 description 2
208000032382 Ischaemic stroke Diseases 0.000 description 2
241000713869 Moloney murine leukemia virus Species 0.000 description 2
241001529936 Murinae Species 0.000 description 2
125000000729 N-terminal amino-acid group Chemical group 0.000 description 2
229930193140 Neomycin Natural products 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
108010007127 Pulmonary Surfactant-Associated Protein D Proteins 0.000 description 2
241000714474 Rous sarcoma virus Species 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
VPZKQTYZIVOJDV-LMVFSUKVSA-N Thr-Ala Chemical group C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(O)=O VPZKQTYZIVOJDV-LMVFSUKVSA-N 0.000 description 2
JLRGJRBPOGGCBT-UHFFFAOYSA-N Tolbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 JLRGJRBPOGGCBT-UHFFFAOYSA-N 0.000 description 2
206010047249 Venous thrombosis Diseases 0.000 description 2
239000005862 Whey Substances 0.000 description 2
102000007544 Whey Proteins Human genes 0.000 description 2
108010046377 Whey Proteins Proteins 0.000 description 2
230000007488 abnormal function Effects 0.000 description 2
230000021736 acetylation Effects 0.000 description 2
238000006640 acetylation reaction Methods 0.000 description 2
238000000246 agarose gel electrophoresis Methods 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
238000004220 aggregation Methods 0.000 description 2
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 2
108010087924 alanylproline Proteins 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
239000000883 anti-obesity agent Substances 0.000 description 2
210000001106 artificial yeast chromosome Anatomy 0.000 description 2
125000003118 aryl group Chemical group 0.000 description 2
230000003143 atherosclerotic effect Effects 0.000 description 2
230000009286 beneficial effect Effects 0.000 description 2
UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
210000001185 bone marrow Anatomy 0.000 description 2
210000000481 breast Anatomy 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
238000004422 calculation algorithm Methods 0.000 description 2
239000004202 carbamide Substances 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
230000032823 cell division Effects 0.000 description 2
238000007385 chemical modification Methods 0.000 description 2
229960001761 chlorpropamide Drugs 0.000 description 2
YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 description 2
229950009226 ciglitazone Drugs 0.000 description 2
229920001436 collagen Polymers 0.000 description 2
239000000287 crude extract Substances 0.000 description 2
XVOYSCVBGLVSOL-UHFFFAOYSA-N cysteic acid Chemical compound OC(=O)C(N)CS(O)(=O)=O XVOYSCVBGLVSOL-UHFFFAOYSA-N 0.000 description 2
230000001461 cytolytic effect Effects 0.000 description 2
230000007547 defect Effects 0.000 description 2
230000003111 delayed effect Effects 0.000 description 2
238000001514 detection method Methods 0.000 description 2
235000015872 dietary supplement Nutrition 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
238000009826 distribution Methods 0.000 description 2
238000004520 electroporation Methods 0.000 description 2
230000008030 elimination Effects 0.000 description 2
238000003379 elimination reaction Methods 0.000 description 2
229940088598 enzyme Drugs 0.000 description 2
210000003743 erythrocyte Anatomy 0.000 description 2
230000007717 exclusion Effects 0.000 description 2
230000020764 fibrinolysis Effects 0.000 description 2
235000012631 food intake Nutrition 0.000 description 2
230000037406 food intake Effects 0.000 description 2
238000009472 formulation Methods 0.000 description 2
BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
239000000499 gel Substances 0.000 description 2
238000001476 gene delivery Methods 0.000 description 2
210000004602 germ cell Anatomy 0.000 description 2
208000004104 gestational diabetes Diseases 0.000 description 2
229960004580 glibenclamide Drugs 0.000 description 2
229960004346 glimepiride Drugs 0.000 description 2
WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 description 2
229960001381 glipizide Drugs 0.000 description 2
ZJJXGWJIGJFDTL-UHFFFAOYSA-N glipizide Chemical compound C1=NC(C)=CN=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZJJXGWJIGJFDTL-UHFFFAOYSA-N 0.000 description 2
ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 description 2
230000036541 health Effects 0.000 description 2
230000011132 hemopoiesis Effects 0.000 description 2
239000000833 heterodimer Substances 0.000 description 2
102000055729 human ATRN Human genes 0.000 description 2
102000045598 human DPP4 Human genes 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
230000001976 improved effect Effects 0.000 description 2
230000006698 induction Effects 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
230000003914 insulin secretion Effects 0.000 description 2
230000001788 irregular Effects 0.000 description 2
238000002955 isolation Methods 0.000 description 2
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
239000002609 medium Substances 0.000 description 2
239000012528 membrane Substances 0.000 description 2
210000004379 membrane Anatomy 0.000 description 2
XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical group CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 2
229960003105 metformin Drugs 0.000 description 2
238000007069 methylation reaction Methods 0.000 description 2
230000000813 microbial effect Effects 0.000 description 2
239000000178 monomer Substances 0.000 description 2
DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 2
208000010125 myocardial infarction Diseases 0.000 description 2
210000000107 myocyte Anatomy 0.000 description 2
229960004927 neomycin Drugs 0.000 description 2
230000009826 neoplastic cell growth Effects 0.000 description 2
230000001019 normoglycemic effect Effects 0.000 description 2
235000016709 nutrition Nutrition 0.000 description 2
230000002611 ovarian Effects 0.000 description 2
210000001672 ovary Anatomy 0.000 description 2
125000001151 peptidyl group Chemical group 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
230000036314 physical performance Effects 0.000 description 2
229960005095 pioglitazone Drugs 0.000 description 2
229920002401 polyacrylamide Polymers 0.000 description 2
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
230000035935 pregnancy Effects 0.000 description 2
230000008569 process Effects 0.000 description 2
239000000186 progesterone Substances 0.000 description 2
229960003387 progesterone Drugs 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
150000003212 purines Chemical class 0.000 description 2
208000037803 restenosis Diseases 0.000 description 2
108091008146 restriction endonucleases Proteins 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
238000012106 screening analysis Methods 0.000 description 2
238000002864 sequence alignment Methods 0.000 description 2
210000002363 skeletal muscle cell Anatomy 0.000 description 2
YZHUMGUJCQRKBT-UHFFFAOYSA-M sodium chlorate Chemical compound [Na+].[O-]Cl(=O)=O YZHUMGUJCQRKBT-UHFFFAOYSA-M 0.000 description 2
238000000638 solvent extraction Methods 0.000 description 2
238000000527 sonication Methods 0.000 description 2
ATHGHQPFGPMSJY-UHFFFAOYSA-N spermidine Chemical compound NCCCCNCCCN ATHGHQPFGPMSJY-UHFFFAOYSA-N 0.000 description 2
PFNFFQXMRSDOHW-UHFFFAOYSA-N spermine Chemical compound NCCCNCCCCNCCCN PFNFFQXMRSDOHW-UHFFFAOYSA-N 0.000 description 2
238000003153 stable transfection Methods 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 2
230000009469 supplementation Effects 0.000 description 2
229960002277 tolazamide Drugs 0.000 description 2
OUDSBRTVNLOZBN-UHFFFAOYSA-N tolazamide Chemical compound C1=CC(C)=CC=C1S(=O)(=O)NC(=O)NN1CCCCCC1 OUDSBRTVNLOZBN-UHFFFAOYSA-N 0.000 description 2
229960005371 tolbutamide Drugs 0.000 description 2
230000007704 transition Effects 0.000 description 2
230000014621 translational initiation Effects 0.000 description 2
238000002054 transplantation Methods 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
210000004291 uterus Anatomy 0.000 description 2
238000012800 visualization Methods 0.000 description 2
QNRXNRGSOJZINA-QMMMGPOBSA-N (2s)-2,3-dihydro-1h-indole-2-carboxylic acid Chemical compound C1=CC=C2N[C@H](C(=O)O)CC2=C1 QNRXNRGSOJZINA-QMMMGPOBSA-N 0.000 description 1
DVVNPYAVFWSKAB-LURJTMIESA-N (2s)-2-(butylazaniumyl)propanoate Chemical compound CCCCN[C@@H](C)C(O)=O DVVNPYAVFWSKAB-LURJTMIESA-N 0.000 description 1
BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 1
NPDBDJFLKKQMCM-SCSAIBSYSA-N (2s)-2-amino-3,3-dimethylbutanoic acid Chemical compound CC(C)(C)[C@H](N)C(O)=O NPDBDJFLKKQMCM-SCSAIBSYSA-N 0.000 description 1
JHHOFXBPLJDHOR-AXDSSHIGSA-N (2s)-4-phenylpyrrolidine-2-carboxylic acid Chemical compound C1N[C@H](C(=O)O)CC1C1=CC=CC=C1 JHHOFXBPLJDHOR-AXDSSHIGSA-N 0.000 description 1
DNXIKVLOVZVMQF-UHFFFAOYSA-N (3beta,16beta,17alpha,18beta,20alpha)-17-hydroxy-11-methoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-yohimban-16-carboxylic acid, methyl ester Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(C(=O)OC)C(O)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 DNXIKVLOVZVMQF-UHFFFAOYSA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
JFMNKDRNEZZRBW-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline-3-carboxamide Chemical class C1=CC=C2CNC(C(=O)N)CC2=C1 JFMNKDRNEZZRBW-UHFFFAOYSA-N 0.000 description 1
BWKMGYQJPOAASG-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid Chemical compound C1=CC=C2CNC(C(=O)O)CC2=C1 BWKMGYQJPOAASG-UHFFFAOYSA-N 0.000 description 1
CXCHEKCRJQRVNG-UHFFFAOYSA-N 2,2,2-trifluoroethanesulfonyl chloride Chemical compound FC(F)(F)CS(Cl)(=O)=O CXCHEKCRJQRVNG-UHFFFAOYSA-N 0.000 description 1
ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 2,3-dimethylbutane Chemical group CC(C)C(C)C ZFFMLCVRJBZUDZ-UHFFFAOYSA-N 0.000 description 1
OGNSCSPNOLGXSM-UHFFFAOYSA-N 2,4-diaminobutyric acid Chemical compound NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
IHBAVXVTGLANPI-QMMMGPOBSA-N 2-amino-3-methyl-1-pyrrolidin-1-yl-butan-1-one Chemical group CC(C)[C@H](N)C(=O)N1CCCC1 IHBAVXVTGLANPI-QMMMGPOBSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
PBBGSZCBWVPOOL-HDICACEKSA-N 4-[(1r,2s)-1-ethyl-2-(4-hydroxyphenyl)butyl]phenol Chemical compound C1([C@H](CC)[C@H](CC)C=2C=CC(O)=CC=2)=CC=C(O)C=C1 PBBGSZCBWVPOOL-HDICACEKSA-N 0.000 description 1
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
102100024959 5-hydroxytryptamine receptor 2C Human genes 0.000 description 1
101710138093 5-hydroxytryptamine receptor 2C Proteins 0.000 description 1
SLXKOJJOQWFEFD-UHFFFAOYSA-N 6-aminohexanoic acid Chemical compound NCCCCCC(O)=O SLXKOJJOQWFEFD-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
102100031786 Adiponectin Human genes 0.000 description 1
108010076365 Adiponectin Proteins 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
102000006822 Agouti Signaling Protein Human genes 0.000 description 1
108010072151 Agouti Signaling Protein Proteins 0.000 description 1
102100038920 Alpha-S1-casein Human genes 0.000 description 1
201000005670 Anovulation Diseases 0.000 description 1
206010002659 Anovulatory cycle Diseases 0.000 description 1
208000031104 Arterial Occlusive disease Diseases 0.000 description 1
241000271566 Aves Species 0.000 description 1
244000063299 Bacillus subtilis Species 0.000 description 1
235000014469 Bacillus subtilis Nutrition 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
UYIFTLBWAOGQBI-BZDYCCQFSA-N Benzhormovarine Chemical compound C([C@@H]1[C@@H](C2=CC=3)CC[C@]4([C@H]1CC[C@@H]4O)C)CC2=CC=3OC(=O)C1=CC=CC=C1 UYIFTLBWAOGQBI-BZDYCCQFSA-N 0.000 description 1
206010006482 Bronchospasm Diseases 0.000 description 1
101100421200 Caenorhabditis elegans sep-1 gene Proteins 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
102100032378 Carboxypeptidase E Human genes 0.000 description 1
108010058255 Carboxypeptidase H Proteins 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
241000700198 Cavia Species 0.000 description 1
102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
108090000317 Chymotrypsin Proteins 0.000 description 1
108091062157 Cis-regulatory element Proteins 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
239000003155 DNA primer Substances 0.000 description 1
102000052510 DNA-Binding Proteins Human genes 0.000 description 1
108700020911 DNA-Binding Proteins Proteins 0.000 description 1
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
108010016626 Dipeptides Proteins 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
102100031780 Endonuclease Human genes 0.000 description 1
241000701867 Enterobacteria phage T7 Species 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000283074 Equus asinus Species 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
108060002716 Exonuclease Proteins 0.000 description 1
108091006020 Fc-tagged proteins Proteins 0.000 description 1
108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
102400000321 Glucagon Human genes 0.000 description 1
108060003199 Glucagon Proteins 0.000 description 1
206010018429 Glucose tolerance impaired Diseases 0.000 description 1
108010051815 Glutamyl endopeptidase Proteins 0.000 description 1
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
108010023302 HDL Cholesterol Proteins 0.000 description 1
101710154606 Hemagglutinin Proteins 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
229920000209 Hexadimethrine bromide Polymers 0.000 description 1
101000741048 Homo sapiens Alpha-S1-casein Proteins 0.000 description 1
101150013372 Htr2c gene Proteins 0.000 description 1
102000002265 Human Growth Hormone Human genes 0.000 description 1
108010000521 Human Growth Hormone Proteins 0.000 description 1
239000000854 Human Growth Hormone Substances 0.000 description 1
241000701109 Human adenovirus 2 Species 0.000 description 1
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
208000001953 Hypotension Diseases 0.000 description 1
206010022714 Intestinal ulcer Diseases 0.000 description 1
SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 1
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
ZGUNAGUHMKGQNY-ZETCQYMHSA-N L-alpha-phenylglycine zwitterion Chemical compound OC(=O)[C@@H](N)C1=CC=CC=C1 ZGUNAGUHMKGQNY-ZETCQYMHSA-N 0.000 description 1
RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
XIGSAGMEBXLVJJ-YFKPBYRVSA-N L-homocitrulline Chemical compound NC(=O)NCCCC[C@H]([NH3+])C([O-])=O XIGSAGMEBXLVJJ-YFKPBYRVSA-N 0.000 description 1
SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 1
LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
HXEACLLIILLPRG-YFKPBYRVSA-N L-pipecolic acid Chemical compound [O-]C(=O)[C@@H]1CCCC[NH2+]1 HXEACLLIILLPRG-YFKPBYRVSA-N 0.000 description 1
125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
DZLNHFMRPBPULJ-VKHMYHEASA-N L-thioproline Chemical compound OC(=O)[C@@H]1CSCN1 DZLNHFMRPBPULJ-VKHMYHEASA-N 0.000 description 1
125000000510 L-tryptophano group Chemical group [H]C1=C([H])C([H])=C2N([H])C([H])=C(C([H])([H])[C@@]([H])(C(O[H])=O)N([H])[*])C2=C1[H] 0.000 description 1
102000008192 Lactoglobulins Human genes 0.000 description 1
108010060630 Lactoglobulins Proteins 0.000 description 1
208000009481 Laryngeal Edema Diseases 0.000 description 1
206010023845 Laryngeal oedema Diseases 0.000 description 1
108090001090 Lectins Proteins 0.000 description 1
102000004856 Lectins Human genes 0.000 description 1
108010036940 Levansucrase Proteins 0.000 description 1
229940127470 Lipase Inhibitors Drugs 0.000 description 1
101150110867 MC4R gene Proteins 0.000 description 1
102000001796 Melanocortin 4 receptors Human genes 0.000 description 1
241000713333 Mouse mammary tumor virus Species 0.000 description 1
241000714177 Murine leukemia virus Species 0.000 description 1
125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
KAFHLONDOVSENM-HNNXBMFYSA-N O-Benzyl-L-tyrosine Chemical compound C1=CC(C[C@H](N)C(O)=O)=CC=C1OCC1=CC=CC=C1 KAFHLONDOVSENM-HNNXBMFYSA-N 0.000 description 1
206010030113 Oedema Diseases 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
108091006006 PEGylated Proteins Proteins 0.000 description 1
101150093308 POMC gene Proteins 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
101710182846 Polyhedrin Proteins 0.000 description 1
208000004880 Polyuria Diseases 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
108010069820 Pro-Opiomelanocortin Proteins 0.000 description 1
239000000683 Pro-Opiomelanocortin Substances 0.000 description 1
102100027467 Pro-opiomelanocortin Human genes 0.000 description 1
101710176177 Protein A56 Proteins 0.000 description 1
108010029485 Protein Isoforms Proteins 0.000 description 1
102000001708 Protein Isoforms Human genes 0.000 description 1
102100029796 Protein S100-A10 Human genes 0.000 description 1
101710110950 Protein S100-A10 Proteins 0.000 description 1
102100027845 Pulmonary surfactant-associated protein D Human genes 0.000 description 1
CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical class C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
LCQMZZCPPSWADO-UHFFFAOYSA-N Reserpilin Natural products COC(=O)C1COCC2CN3CCc4c([nH]c5cc(OC)c(OC)cc45)C3CC12 LCQMZZCPPSWADO-UHFFFAOYSA-N 0.000 description 1
QEVHRUUCFGRFIF-SFWBKIHZSA-N Reserpine Natural products O=C(OC)[C@@H]1[C@H](OC)[C@H](OC(=O)c2cc(OC)c(OC)c(OC)c2)C[C@H]2[C@@H]1C[C@H]1N(C2)CCc2c3c([nH]c12)cc(OC)cc3 QEVHRUUCFGRFIF-SFWBKIHZSA-N 0.000 description 1
241000712909 Reticuloendotheliosis virus Species 0.000 description 1
206010038997 Retroviral infections Diseases 0.000 description 1
101100386054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) CYS3 gene Proteins 0.000 description 1
241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
108010077895 Sarcosine Proteins 0.000 description 1
208000034189 Sclerosis Diseases 0.000 description 1
241000256251 Spodoptera frugiperda Species 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
108010022394 Threonine synthase Proteins 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
108020004440 Thymidine kinase Proteins 0.000 description 1
102000004357 Transferases Human genes 0.000 description 1
108090000992 Transferases Proteins 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108010021436 Type 4 Melanocortin Receptor Proteins 0.000 description 1
208000024780 Urticaria Diseases 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
239000007801 affinity label Substances 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
238000012867 alanine scanning Methods 0.000 description 1
125000003545 alkoxy group Chemical group 0.000 description 1
230000009435 amidation Effects 0.000 description 1
238000007112 amidation reaction Methods 0.000 description 1
150000001408 amides Chemical group 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229960002684 aminocaproic acid Drugs 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
238000012870 ammonium sulfate precipitation Methods 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
238000005571 anion exchange chromatography Methods 0.000 description 1
150000001450 anions Chemical class 0.000 description 1
231100000552 anovulation Toxicity 0.000 description 1
229910052586 apatite Inorganic materials 0.000 description 1
208000021328 arterial occlusion Diseases 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
210000004507 artificial chromosome Anatomy 0.000 description 1
208000006673 asthma Diseases 0.000 description 1
238000002869 basic local alignment search tool Methods 0.000 description 1
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
230000008827 biological function Effects 0.000 description 1
229960000074 biopharmaceutical Drugs 0.000 description 1
235000020958 biotin Nutrition 0.000 description 1
229960002685 biotin Drugs 0.000 description 1
239000011616 biotin Substances 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
230000006583 body weight regulation Effects 0.000 description 1
210000000069 breast epithelial cell Anatomy 0.000 description 1
230000007885 bronchoconstriction Effects 0.000 description 1
230000023852 carbohydrate metabolic process Effects 0.000 description 1
235000021256 carbohydrate metabolism Nutrition 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
238000005277 cation exchange chromatography Methods 0.000 description 1
230000021164 cell adhesion Effects 0.000 description 1
230000022131 cell cycle Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
230000003196 chaotropic effect Effects 0.000 description 1
238000001311 chemical methods and process Methods 0.000 description 1
229960005091 chloramphenicol Drugs 0.000 description 1
230000002759 chromosomal effect Effects 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
229960002376 chymotrypsin Drugs 0.000 description 1
229960002173 citrulline Drugs 0.000 description 1
235000013477 citrulline Nutrition 0.000 description 1
230000009194 climbing Effects 0.000 description 1
238000012411 cloning technique Methods 0.000 description 1
238000010835 comparative analysis Methods 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000001447 compensatory effect Effects 0.000 description 1
238000010668 complexation reaction Methods 0.000 description 1
208000012696 congenital leptin deficiency Diseases 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
238000010276 construction Methods 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
238000012258 culturing Methods 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
125000004093 cyano group Chemical group *C#N 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
230000002950 deficient Effects 0.000 description 1
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
229960003957 dexamethasone Drugs 0.000 description 1
150000005690 diesters Chemical class 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
230000004069 differentiation Effects 0.000 description 1
102000004419 dihydrofolate reductase Human genes 0.000 description 1
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000000857 drug effect Effects 0.000 description 1
230000001516 effect on protein Effects 0.000 description 1
210000002308 embryonic cell Anatomy 0.000 description 1
230000019439 energy homeostasis Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
229950002007 estradiol benzoate Drugs 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
238000012869 ethanol precipitation Methods 0.000 description 1
125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
230000010429 evolutionary process Effects 0.000 description 1
230000029142 excretion Effects 0.000 description 1
230000001747 exhibiting effect Effects 0.000 description 1
102000013165 exonuclease Human genes 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
210000003414 extremity Anatomy 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
239000012467 final product Substances 0.000 description 1
230000004907 flux Effects 0.000 description 1
230000022244 formylation Effects 0.000 description 1
238000006170 formylation reaction Methods 0.000 description 1
108700004026 gag Genes Proteins 0.000 description 1
229960003692 gamma aminobutyric acid Drugs 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000010448 genetic screening Methods 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
229960004666 glucagon Drugs 0.000 description 1
MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
238000007446 glucose tolerance test Methods 0.000 description 1
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
230000036252 glycation Effects 0.000 description 1
125000003147 glycosyl group Chemical group 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
230000037219 healthy weight Effects 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
125000005842 heteroatom Chemical group 0.000 description 1
239000008241 heterogeneous mixture Substances 0.000 description 1
229950001996 hexestrol Drugs 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
238000004191 hydrophobic interaction chromatography Methods 0.000 description 1
229960002591 hydroxyproline Drugs 0.000 description 1
230000036543 hypotension Effects 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
238000001802 infusion Methods 0.000 description 1
208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
208000014674 injury Diseases 0.000 description 1
150000002484 inorganic compounds Chemical class 0.000 description 1
229910010272 inorganic material Inorganic materials 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000011835 investigation Methods 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
125000000741 isoleucyl group Chemical group [H]N([H])C(C(C([H])([H])[H])C([H])([H])C([H])([H])[H])C(=O)O* 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
230000000155 isotopic effect Effects 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
230000006651 lactation Effects 0.000 description 1
239000002523 lectin Substances 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
125000003473 lipid group Chemical group 0.000 description 1
230000004130 lipolysis Effects 0.000 description 1
235000021056 liquid food Nutrition 0.000 description 1
210000005228 liver tissue Anatomy 0.000 description 1
230000007774 longterm Effects 0.000 description 1
208000018773 low birth weight Diseases 0.000 description 1
231100000533 low birth weight Toxicity 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
208000001022 morbid obesity Diseases 0.000 description 1
230000037257 muscle growth Effects 0.000 description 1
210000001087 myotubule Anatomy 0.000 description 1
230000023578 negative regulation of cell adhesion Effects 0.000 description 1
230000017066 negative regulation of growth Effects 0.000 description 1
208000029140 neonatal diabetes Diseases 0.000 description 1
201000008383 nephritis Diseases 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
239000002767 noradrenalin uptake inhibitor Substances 0.000 description 1
230000000474 nursing effect Effects 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
238000005457 optimization Methods 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 description 1
229960001243 orlistat Drugs 0.000 description 1
229960003104 ornithine Drugs 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
229940055729 papain Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000006320 pegylation Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
210000004197 pelvis Anatomy 0.000 description 1
VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
210000001322 periplasm Anatomy 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical class [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 description 1
UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 description 1
NOFRKKIRSYFOAL-WCCKRBBISA-N phosphoric acid;(2s)-pyrrolidine-2-carboxylic acid Chemical class OP(O)(O)=O.OC(=O)[C@@H]1CCCN1 NOFRKKIRSYFOAL-WCCKRBBISA-N 0.000 description 1
230000026731 phosphorylation Effects 0.000 description 1
238000006366 phosphorylation reaction Methods 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
WKNDBJMYXHMSER-UHFFFAOYSA-N piperidin-1-yl dihydrogen phosphate Chemical compound OP(O)(=O)ON1CCCCC1 WKNDBJMYXHMSER-UHFFFAOYSA-N 0.000 description 1
210000001778 pluripotent stem cell Anatomy 0.000 description 1
229920000768 polyamine Polymers 0.000 description 1
206010036067 polydipsia Diseases 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000037452 priming Effects 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
210000001236 prokaryotic cell Anatomy 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
230000012846 protein folding Effects 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
239000012264 purified product Substances 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
125000000719 pyrrolidinyl group Chemical group 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
238000005932 reductive alkylation reaction Methods 0.000 description 1
BJOIZNZVOZKDIG-MDEJGZGSSA-N reserpine Chemical compound O([C@H]1[C@@H]([C@H]([C@H]2C[C@@H]3C4=C([C]5C=CC(OC)=CC5=N4)CCN3C[C@H]2C1)C(=O)OC)OC)C(=O)C1=CC(OC)=C(OC)C(OC)=C1 BJOIZNZVOZKDIG-MDEJGZGSSA-N 0.000 description 1
229960003147 reserpine Drugs 0.000 description 1
230000000241 respiratory effect Effects 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
210000003705 ribosome Anatomy 0.000 description 1
MDMGHDFNKNZPAU-UHFFFAOYSA-N roserpine Natural products C1C2CN3CCC(C4=CC=C(OC)C=C4N4)=C4C3CC2C(OC(C)=O)C(OC)C1OC(=O)C1=CC(OC)=C(OC)C(OC)=C1 MDMGHDFNKNZPAU-UHFFFAOYSA-N 0.000 description 1
229940043230 sarcosine Drugs 0.000 description 1
238000007790 scraping Methods 0.000 description 1
238000007423 screening assay Methods 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
239000003772 serotonin uptake inhibitor Substances 0.000 description 1
UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
229960004425 sibutramine Drugs 0.000 description 1
230000009645 skeletal growth Effects 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
239000012279 sodium borohydride Substances 0.000 description 1
229910000033 sodium borohydride Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
229940063673 spermidine Drugs 0.000 description 1
229940063675 spermine Drugs 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
101150035983 str1 gene Proteins 0.000 description 1
125000001424 substituent group Chemical group 0.000 description 1
125000003107 substituted aryl group Chemical group 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000000153 supplemental effect Effects 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
208000001608 teratocarcinoma Diseases 0.000 description 1
238000011191 terminal modification Methods 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
230000005030 transcription termination Effects 0.000 description 1
238000010361 transduction Methods 0.000 description 1
230000026683 transduction Effects 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
238000003146 transient transfection Methods 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
229960001322 trypsin Drugs 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
210000000689 upper leg Anatomy 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
230000001457 vasomotor Effects 0.000 description 1
208000001319 vasomotor rhinitis Diseases 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
229920003169 water-soluble polymer Polymers 0.000 description 1
238000004260 weight control Methods 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1